OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Rating of “Hold” by Brokerages

OPKO Health, Inc. (NASDAQ:OPK) has been assigned an average recommendation of “Hold” from the seven ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $2.2833.

OPK has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. initiated coverage on shares of OPKO Health in a report on Thursday, November 20th. They set a “neutral” rating for the company. Jefferies Financial Group restated a “hold” rating and set a $1.60 price objective (down from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. Barrington Research restated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research note on Thursday, October 30th. Wall Street Zen raised OPKO Health from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a report on Wednesday, October 8th.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost bought 580,000 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was purchased at an average price of $1.33 per share, with a total value of $771,400.00. Following the completion of the acquisition, the chief executive officer owned 216,706,448 shares of the company’s stock, valued at $288,219,575.84. The trade was a 0.27% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders bought a total of 1,843,300 shares of company stock worth $2,421,491 over the last three months. 49.69% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. AWM Investment Company Inc. raised its position in shares of OPKO Health by 42.3% during the first quarter. AWM Investment Company Inc. now owns 1,850,000 shares of the biotechnology company’s stock worth $3,071,000 after acquiring an additional 550,000 shares during the last quarter. Geode Capital Management LLC increased its position in OPKO Health by 23.7% during the 2nd quarter. Geode Capital Management LLC now owns 10,424,473 shares of the biotechnology company’s stock valued at $13,763,000 after purchasing an additional 1,995,633 shares during the period. Washington Growth Strategies LLC increased its position in shares of OPKO Health by 67,806,100.0% during the second quarter. Washington Growth Strategies LLC now owns 1,356,124 shares of the biotechnology company’s stock worth $1,790,000 after buying an additional 1,356,122 shares during the period. PFG Investments LLC raised its stake in OPKO Health by 3.9% during the second quarter. PFG Investments LLC now owns 1,265,125 shares of the biotechnology company’s stock worth $1,670,000 after buying an additional 47,765 shares during the last quarter. Finally, Capital Advisors Inc. OK lifted its holdings in OPKO Health by 5.7% in the second quarter. Capital Advisors Inc. OK now owns 370,000 shares of the biotechnology company’s stock valued at $488,000 after buying an additional 20,000 shares during the period. Institutional investors own 64.63% of the company’s stock.

OPKO Health Stock Up 0.8%

Shares of NASDAQ OPK opened at $1.28 on Thursday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.32 and a current ratio of 3.70. OPKO Health has a 52 week low of $1.11 and a 52 week high of $2.04. The stock has a market capitalization of $982.66 million, a P/E ratio of -5.12 and a beta of 1.39. The stock’s fifty day moving average is $1.33 and its 200 day moving average is $1.37.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.05. OPKO Health had a negative net margin of 28.10% and a negative return on equity of 13.67%. The business had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $165.74 million. During the same quarter in the prior year, the business posted $0.03 earnings per share. OPKO Health’s revenue was down 12.6% compared to the same quarter last year. Sell-side analysts forecast that OPKO Health will post -0.25 earnings per share for the current fiscal year.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.